



Why U.S. Biomedical Research Leadership Matters for Every Family

The United States has long led the global biomedical research and pharmaceutical development industry, but that leadership is eroding faster than many realize.

A combination of U.S. policies that incentivize offshore investment, along with China's rapid biotech growth, has created a concerning reality for American families: more of our medicines are being developed, tested, and manufactured in a country with far less rigorous standards than our own.¹

Preserving American biomedical leadership isn't just an economic issue; it's a threat to patient safety at home.

Chinese Biomedical Influence Grows

China's control of the market is increasing while U.S. innovation moves overseas, leading to:

- Loss of American biomedical jobs
- Increased risk of supply chain disruption
- Diminished American global leadership



46% of new drugs entering human trials come from China, up from just 17% a decade ago.²



U.S. funding for biotech is at its lowest in over 20 years as funding moves to other sectors and overseas.³

1 Frontiers in Medicine. (2023). *A study on the normative path of ethics review in China: based on the perspective of Panopticism*
2 Goldman Sachs Research. (2025). *China Is Increasing Its Share of Global Drug Development*
3 Crunchbase. (2025). *Biotech Share Of US Funding Hits Lowest Point In Crunchbase History*

The threat to American families isn't just hypothetical. China has a documented history of pharmaceutical safety incidents, including the 2008 Chinese heparin crisis that killed 81 people and left nearly 800 severely injured.


Offshoring U.S. biomedical research means tomorrow's medical breakthroughs could sacrifice safety, efficacy, and trust for critical treatments in areas like:

- **Cancer**
- **Emerging infectious diseases**
- **Pediatric health**
- **Rare diseases**

Chinese Clinical Trials Increase 25% Within Ten Years⁴

U.S. leadership in clinical trials research is set to be overtaken as companies seek out lower costs and less rigorous standards overseas.

Foreign-made generic medications are almost twice as likely⁵ to cause severe adverse events than their U.S.-made counterparts.



Help us preserve U.S. biomedical research leadership and standards that keep our children safe.



CURECOALITION.ORG

⁴ Contrary Research. (2025). *The State of the US-China Biotech Race*

⁵ Production and Operations Management. (2025). *Are All Generic Drugs Created Equal? An Empirical Analysis of Generic Drug Manufacturing Location and Serious Drug Adverse Events*